As of March 31, 2008, Nephros had cash and cash equivalents in the amount of $2,505,000. In addition, Nephros had $4,286,000 invested in auction rate securities, which are classified as non-current investments at March 31, 2008.
ESRD Clinical Trial Update
In the first quarter of 2008, Nephros completed enrollment in the Company's pivotal U.S. clinical trial for the OLpur(TM) H2H(TM) Hemodiafiltration Module and OLpur(TM) MD 220 Hemodiafilter products for the treatment of patients with end-stage renal disease (ESRD). Nephros anticipates that all enrolled patients will have completed the study protocol by June 1, 2008.
"In the second half of 2008, we plan to seek FDA approval to market our leading-edge products here in the U.S.," said Mr. Barta. Nephros believes that, if approved in 2008, its mid-dilution HDF technology would be the first approved online HDF therapy in the United States.
Water Ultrafiltration Products
Nephros is finalizing improvements to the functionality and ergonomics of its water ultrafiltration products and has applied for stringent water filter performance certifications from NSF International, an independent non-profit product evaluation laboratory. NSF has completed its initial stage of testing, and Nephros anticipates final completion of required NSF testing during the second quarter of 2008.
Nephros expects to continue its military product development with support from its existing cost contract with the Office of Naval Research and other contracts that may arise out of the U.S. Department of Defense appropriations that have been made for such purpose.
About Nephros, Inc.
Nephros, Inc., headquartered in New York, is a medical devi
|SOURCE Nephros, Inc.|
Copyright©2008 PR Newswire.
All rights reserved